Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lodise

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 5, 2024
Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infectionsHeather M Draper, Michael J Rybak, Kerry L LaPlante, et al.
Open Forum Infectious Diseases|May 29, 2020
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical TrialsThomas Lodise, Sam Colman, Daniel S Stein, et al.
Advances in Therapy|April 24, 2023
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USAThomas Lodise, Amy Guo, Min Yang, et al.
Advances in Therapy|April 24, 2023
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the USThomas Lodise, Amy Guo, Min Yang, et al.
Advances in Therapy|May 21, 2023
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost SynthesisKelly R Reveles, Min Yang, Viviana Garcia-Horton, et al.
Open Forum Infectious Diseases|December 13, 2018
Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York StateElliot L Rank, Thomas Lodise, Lisa Avery, et al.
JAMA Network Open|January 16, 2019
Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa InfectionSara Y Tartof, Jennifer L Kuntz, Lie H Chen, et al.
Journal of the American Pharmacists Association : Japha|May 11, 2010
Privacy in the pharmacy environment: analysis of observations from inside the pharmacyRobert A Bednarczyk, Jessica A Nadeau, Christopher F Davis, et al.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 5, 2024
Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infectionsHeather M Draper, Michael J Rybak, Kerry L LaPlante, et al.
Open Forum Infectious Diseases|May 29, 2020
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical TrialsThomas Lodise, Sam Colman, Daniel S Stein, et al.
Advances in Therapy|April 24, 2023
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USAThomas Lodise, Amy Guo, Min Yang, et al.
Advances in Therapy|April 24, 2023
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the USThomas Lodise, Amy Guo, Min Yang, et al.
Advances in Therapy|May 21, 2023
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost SynthesisKelly R Reveles, Min Yang, Viviana Garcia-Horton, et al.
Open Forum Infectious Diseases|December 13, 2018
Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York StateElliot L Rank, Thomas Lodise, Lisa Avery, et al.
JAMA Network Open|January 16, 2019
Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa InfectionSara Y Tartof, Jennifer L Kuntz, Lie H Chen, et al.
Journal of the American Pharmacists Association : Japha|May 11, 2010
Privacy in the pharmacy environment: analysis of observations from inside the pharmacyRobert A Bednarczyk, Jessica A Nadeau, Christopher F Davis, et al.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Pageof 4